Novartis' blockbuster Gilenya exposed to generics in short term amid Supreme Court appeal

As Novartis awaits the U.S. Supreme Court’s decision on whether to take up its Gilenya patent dispute, the high court has cleared the way for copies of the nearly $3 billion multiple sclerosis blockbuster to hit the market in the short term.